Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
WBRT shows no significant survival benefit in thyroid cancer brain metastases meta-analysis
Whole-brain radiation shows no clear survival benefit for thyroid cancer brain metastases
A systematic review and individual patient data meta-analysis of 247 patients with thyroid cancer brain metastases found whole-brain radiati…
Whole-brain radiation therapy showed no clear survival benefit for patients with thyroid cancer that spread to their brain.
Systemic cancer treatment linked to 5% skeletal muscle loss over 90 days
Cancer treatment linked to muscle loss in large analysis
A systematic review and meta-analysis of 78 studies (n=10,502) found that systemic cancer treatment is associated with a small but significa…
Chemotherapy and immunotherapy may cause muscle loss in cancer patients, a new analysis of 78 studies finds.
cGAS–STING activation correlates with improved survival and enhanced checkpoint blockade response in cancer
Activating a cancer-fighting immune pathway can help tumors shrink but too much may backfire
This narrative review synthesizes evidence on cGAS–STING pathway activation in cancer. The authors report that heightened activity correlate…
Turning on a specific immune pathway helps some cancer patients survive longer, yet overactivating it can cause the immune system to stop wo…
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Giant mesenteric fibromatosis progresses despite targeted therapy and immunotherapy in case report
One patient with a giant tumor progressed despite targeted therapy and immunotherapy
This review of a case report describes a patient with giant abdominal mesenteric fibromatosis who progressed rapidly despite targeted therap…
A single patient with a massive abdominal tumor saw it grow quickly even after receiving advanced drugs, followed by complex surgery.
Molecular markers may improve risk assessment in oral potentially malignant disorders
Molecular tools may improve risk assessment for oral lesions
This narrative review examines the limitations of conventional histopathological grading for oral potentially malignant disorders (OPMDs) an…
A review suggests molecular methods could better assess risk for oral potentially malignant disorders where standard grading is unreliable.
Vaginal irrigation self-management shows conditional support for cervical cancer patients undergoing radiotherapy
Vaginal irrigation helps cervical cancer patients on radiotherapy
This systematic review evaluates vaginal irrigation self-management in patients undergoing radiotherapy for cervical cancer. The analysis in…
A review of 23 trials suggests vaginal irrigation self-care may reduce complications for cervical cancer patients undergoing radiotherapy.
TIL therapy and engineered viral vector immunotherapies show pooled ORR of 37.8% in advanced melanoma
First new analysis in years shows TIL therapy response rates for advanced melanoma
This Bayesian meta-analysis synthesizes data from 13 eligible studies on TIL therapy and engineered viral vector immunotherapies for advance…
A Bayesian meta-analysis of 13 studies finds TIL therapy yields a 49% response rate in advanced melanoma, with moderate certainty for respon…
IL-17-targeted intervention implications for tissue injury remain uncertain due to lack of holistic regulatory perspective
New review explains how IL-17 works differently in injured tissues
This narrative review examines IL-17-targeted interventions for tissue injury. The authors note that the field lacks a holistic perspective …
A new review explains how IL-17 behaves differently in injured tissues, offering fresh ideas for tailored treatment strategies.
Adding docetaxel to ADT and RT cuts mortality in high-risk prostate cancer with normal testosterone
Adding chemo to hormone therapy for prostate cancer may depend on testosterone levels
This RCT subgroup analysis found that adding docetaxel to radiation and ADT significantly reduced all-cause mortality in nonmetastatic high-…
Adding chemo to standard therapy for high-risk prostate cancer may only help men with normal testosterone levels, a long-term study suggests…
T cell-based therapies show promise but face barriers in solid tumors
CAR-T and TIL therapies face hurdles in treating solid tumors
This narrative review examines CAR-T, TIL, and TCE therapies for hematologic and solid malignancies. Key challenges include on-target/off-tu…
A review notes that CAR-T, TIL, and TCE therapies struggle with tumor microenvironments and manufacturing issues for solid cancers.